FDA 510(k)
FDA class 2
Substantially Equivalent
🇩🇪 Germany
N Latex Cystatin C; N Protein Standard UY
K Number: K171072
·
Decision May 12, 2017
Classifications
1
FEI Numbers
24
Registration Numbers
24
Same Product Code
21
Applicant Total
19
Review Days
32
Research this 510(k) in seconds
The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.
Free to try · every answer cites its records
Basic Information
- Device Name
- N Latex Cystatin C; N Protein Standard UY
- K Number
- K171072
- Device Class
- FDA class 2
- Clearance Type
- Traditional
- Regulation Number
- 862.1225
- Medical Specialty
- Clinical Chemistry
- Decision
- Substantially Equivalent
- Statement or Summary
- Summary
- Applicant
- Siemens Healthcare Diagnostics Products GmbH
- Date Received
- April 10, 2017
- Decision Date
- May 12, 2017
- Product Code
- NDY
- Advisory Committee
- Clinical Chemistry
- Review Advisory Committee
- CH
- Third Party
- N
Classifications
This FDA 510(k) entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| NDY | Test, Cystatin C | FDA class 2 | Clinical Chemistry |
Similar 510(k) Clearances
Other 510(k) clearances with the same product code (NDY), ordered by most recent decision date.
Cystatin C
FDA 510(k)
FDA Class 2
·Clinical Chemistry
ADVIA Chemistry Cystatin C_2 Assay (CYSC_2)
FDA 510(k)
FDA Class 2
·Clinical Chemistry
Tina-quant Cystatin C Gen.2
FDA 510(k)
FDA Class 2
·Clinical Chemistry
COBAS C TINA-QUANT CYSTATIN C GEN.2 ASSAY, C.F.A.S. CYSTATIN C CALIBRATOR, CYSTATIN C GEN.2 CONTROL SET
FDA 510(k)
FDA Class 2
·Clinical Chemistry
DIAZYME CYSTATIN C POC TEST KIT
FDA 510(k)
FDA Class 2
·Clinical Chemistry
K-ASSAY CYSTATIN C REAGENT, CALIBRATOR AND CONTROL
FDA 510(k)
FDA Class 2
·Clinical Chemistry
Other Clearances by Siemens Healthcare Diagnostics Products GmbH
| K Number | Device Name | ||
|---|---|---|---|
| K240315 | INNOVANCE Anti-Xa (OPPU05); INNOVANCE Apixaban Standards (OPPW05); INNOVANCE Apixaban Controls (OPPS05) | Oct 10, 2024 | Substantially Equivalent |
| K233663 | N Antisera to Human Immunoglobulins (IgG, IgA, and IgM) | Dec 13, 2023 | Substantially Equivalent |
| K220728 | vWF Ag | Jun 2, 2023 | Substantially Equivalent |
| K212559 | CardioPhase® hsCRP | Dec 16, 2022 | Substantially Equivalent |
| DEN200067 | INNOVANCE VWF Ac | Sep 29, 2022 | Unknown |
| K212379 | N Latex FLC kappa, N Latex FLC lambda | Mar 2, 2022 | Substantially Equivalent |
| K201496 | N Latex FLC kappa, N Latex FLC lambda | Oct 29, 2021 | Substantially Equivalent |
| K193047 | N Latex FLC kappa, N Latex FLC lambda | Jul 14, 2021 | Substantially Equivalent |
| K190879 | N Latex FLC kappa, N Latex FLC lambda | May 3, 2019 | Substantially Equivalent |
| K182098 | N Latex FLC kappa assay, N Latex FLC lambda assay | Nov 1, 2018 | Substantially Equivalent |